David J. Graham, MD, MPH

Associate director
US Food and Drug Administration
Silver Spring, United States

Disclosure information not submitted.

Presentation(s):

• Innovative Self-controlled Risk Interval Analysis of Effectiveness of COVID-19 mRNA Booster Vaccination in the Veterans Health Administration, Omicron Predominant Period

  Tuesday, August 27, 2024
  9:00 AM – 9:15 AM CEST

• Comparative bleeding risks among NOAC users for nonvalvular atrial fibrillation aged <65 years in the Sentinel System

  Wednesday, August 28, 2024
  1:30 PM – 1:45 PM CEST